It ’s time to reconsider the three percent discount rate.
Health technology assessment (HTA) guidance often recommends a 3 percent real annual discount rate, the appropriateness of which has received limited attention. This paper seeks to identify an appropriate rate for high-income countries because it can influence projected cost-effectiveness and hence resource allocation recommendations. (Source: Value in Health)
Source: Value in Health - March 8, 2024 Category: International Medicine & Public Health Authors: Joshua T. Cohen Tags: Methodology Source Type: research
Costs and productivity benefits of the VA MISSION Act scribes trial
To improve access, the VA MISSION Act of 2018 mandated a two-year study of medical scribes in Veterans Health Administration specialty clinics and emergency departments. Medical scribes are employed in clinical settings with the goals of increasing provider productivity and satisfaction by minimizing physicians ’ documentation burden. Our objective is to quantify the economic outcomes of the MISSION ACT scribes trial. (Source: Value in Health)
Source: Value in Health - March 8, 2024 Category: International Medicine & Public Health Authors: Paul R. Shafer, Sivagaminathan Palani, Iman Saeed, Aaron Legler, Kyle Barr, Kristina Carvalho, Steven D. Pizer Source Type: research
Methods to include environmental impacts in health economic evaluations and health technology assessments: a scoping review
This study aims to summarise the evidence that exists about methods to include environmental impacts in health economic evaluations and health technology assessments. (Source: Value in Health)
Source: Value in Health - March 8, 2024 Category: International Medicine & Public Health Authors: Jake T.W. Williams, Katy J.L. Bell, Rachael L. Morton, Mbathio Dieng Tags: Systematic Literature Review Source Type: research
Pneumococcal vaccination strategies in 50-year-olds to decrease racial disparities: a US societal perspective cost-effectiveness analysis
This study assesses the impact of expanding pneumococcal vaccination to all 50-year-olds to decrease racial disparities by estimating from the societal perspective, the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) and 15-valent conjugate vaccine followed by 23-valent polysaccharide vaccine (PCV15/PPSV23) for 50-year-olds. (Source: Value in Health)
Source: Value in Health - March 8, 2024 Category: International Medicine & Public Health Authors: Shoroq M. Altawalbeh, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith Source Type: research
Critical Comments by Food and Drug Administration Reviewers on Patient-Reported Outcomes in Food and Drug Administration Regulatory Submissions (2018-2021)
This article examined the inclusion of patient-reported outcome (PRO) data in new drug applications (NDAs) submitted to the Food and Drug Administration (FDA) and approved from 2018 to 2021. The importance of assessing PROs, which capture patients ’ perspectives on the disease and treatment experience, has been underscored by many stakeholders, including regulatory authorities. Despite the increasing inclusion of PRO assessments in registration trials, inclusion of language related to PRO results in approved product labeling varies widely. (Source: Value in Health)
Source: Value in Health - March 6, 2024 Category: International Medicine & Public Health Authors: Christina Slota, Lindsey Norcross, Erin Comerford, Medha Sasane, Ying Zheng, Ari Gnanasakthy Tags: Patient-Reported Outcomes Source Type: research
Critical Comments by FDA Reviewers on Patient-Reported Outcomes in FDA Regulatory Submissions (2018-2021)
This manuscript examines the inclusion of patient-reported outcome (PRO) data in new drug applications (NDAs) submitted to the Food and Drug Administration (FDA) and approved from 2018 through 2021. The importance of assessing PROs, which capture patients ’ perspectives on the disease and treatment experience, has been underscored by many stakeholders, including regulatory authorities. Despite the increasing inclusion of PRO assessments in registration trials, inclusion of language related to PRO results in approved product labeling varies widely. (Source: Value in Health)
Source: Value in Health - March 6, 2024 Category: International Medicine & Public Health Authors: Christina Slota, Lindsey Norcross, Erin Comerford, Medha Sasane, Ying Zheng, Ari Gnanasakthy Source Type: research
A Head-to-Head Comparison of EQ Health and Wellbeing and EQ-5D-5L in Patients, Carers, and General Public in China
This study aimed to understand the psychometric properties of EQ Health and Wellbeing (EQ-HWB) and to examine its relationship with EQ-5D-5L in a sample covering patients, carers, and general public. (Source: Value in Health)
Source: Value in Health - March 4, 2024 Category: International Medicine & Public Health Authors: Chen Long, Zhuxin Mao, Zhihao Yang Tags: Themed Section Source Type: research
Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient Access
This study aimed to evaluate the impact of the National Institute for Health and Care Excellence ’s (NICE) new severity modifier, which has replaced the end-of-life (EoL) premium, on future NICE recommendations, considering past decision-making patterns. (Source: Value in Health)
Source: Value in Health - March 4, 2024 Category: International Medicine & Public Health Authors: Martin W. Njoroge, Matthew Walton, Robert Hodgson Tags: Health Policy Analysis Source Type: research
From Health to Wellbeing: Toward a Monetary Valuation of a Wellbeing-Adjusted Life-Year
This study explored contingent valuation as a method to estimate the monetary value of a wellbeing-adjusted life-year (WALY) as measured by ICEpop Capability Measure for Adults (ICECAP-A). (Source: Value in Health)
Source: Value in Health - March 4, 2024 Category: International Medicine & Public Health Authors: Carolin Brinkmann, Tom Stargardt, Werner B.F. Brouwer Tags: Themed Section Source Type: research
Construct Validity, Reliability, and Responsiveness of the 10-Item Well-being Instrument for Use in Economic Evaluation Studies
This study aimed to assess construct validity, test-retest reliability, and responsiveness of the newly developed 10-item Well-being instrument (WiX). (Source: Value in Health)
Source: Value in Health - March 4, 2024 Category: International Medicine & Public Health Authors: Judith A.M. Bom, Daphne C. Voormolen, Werner B.F. Brouwer, Esther W. de Bekker-Grob, Job van Exel Tags: Themed Section Source Type: research
A head-to-head comparison of EQ health and wellbeing (EQ-HWB) and EQ-5D-5L in patients, carers, and general public in China
To understand the psychometric properties of EQ Health and Wellbeing (EQ-HWB) and to examine its relationship with EQ-5D-5L in a sample covering patients, carers, and general public. (Source: Value in Health)
Source: Value in Health - March 4, 2024 Category: International Medicine & Public Health Authors: Chen Long, Zhuxin Mao, Zhihao Yang Source Type: research
Construct validity, reliability and responsiveness of the 10-item Well-being instrument (WiX) for use in economic evaluation studies
Economic evaluations of interventions in health and social care require outcome measures that capture their full benefits, including those beyond health. The aim of this study was to assess construct validity, test-retest reliability, and responsiveness of the newly developed 10-item Well-being instrument (WiX). (Source: Value in Health)
Source: Value in Health - March 4, 2024 Category: International Medicine & Public Health Authors: Judith A.M. Bom, Daphne C. Voormolen, Werner B.F. Brouwer, Esther W. de Bekker-Grob, Job van Exel Source Type: research
From Health to Wellbeing: Towards a Monetary Valuation of a Wellbeing-Adjusted Life Year
This study explored contingent valuation as a method to estimate the monetary value of a wellbeing-adjusted life year (WALY) as measured by ICECAP-A. (Source: Value in Health)
Source: Value in Health - March 4, 2024 Category: International Medicine & Public Health Authors: Carolin Brinkmann, Tom Stargardt, Werner B.F. Brouwer Source Type: research
Understanding the NICE severity premium: Exploring its implementation and the implications for decision-making and patient access
To evaluate the impact of NICE ’s new severity modifier, which has replaced the end-of-life (EoL) premium, on future NICE recommendations, considering past decision-making patterns. (Source: Value in Health)
Source: Value in Health - March 4, 2024 Category: International Medicine & Public Health Authors: Martin W. Njoroge, Matthew Walton, Robert Hodgson Source Type: research
Multidimensional Thresholding for Individual-Level Preference Elicitation
This article aims to provide the first introduction into the design and analysis of multidimensional thresholding (MDT). (Source: Value in Health)
Source: Value in Health - February 28, 2024 Category: International Medicine & Public Health Authors: Sebastian Heidenreich, Douwe Postmus, Tommi Tervonen Tags: Methodology Source Type: research
